# MASLDPharmacoGeno -- Top Hypothesis Cards (SYNTHETIC DEMO)

> 본 도구는 연구용/참고용입니다. 임상의사결정에 직접 사용하지 마십시오. 생성된 가설은 IRB 승인 및 전문가 검토 후에만 활용하십시오. 유전형 분석 결과는 임상유전학 전문가 해석이 필요합니다.

Top 50 under-explored cells out of 3375 total.

## 1. PNPLA3 rs738409 x efruxifermin x MASH_resolution x Korean_LF_HC x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: MASH resolution without worsening of fibrosis (biopsy)
- Diet: Korean low-fat high-carb (rice-based, ~65% carb)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 2. PNPLA3 rs738409 x efruxifermin x MASH_resolution x Mediterranean x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: MASH resolution without worsening of fibrosis (biopsy)
- Diet: Mediterranean (olive oil, fish, vegetables)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 3. PNPLA3 rs738409 x efruxifermin x MASH_resolution x low_carb x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: MASH resolution without worsening of fibrosis (biopsy)
- Diet: Low-carb (<26% kcal carb)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 4. PNPLA3 rs738409 x efruxifermin x MASH_resolution x ketogenic x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: MASH resolution without worsening of fibrosis (biopsy)
- Diet: Ketogenic (<10% kcal carb, high fat)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 5. PNPLA3 rs738409 x efruxifermin x MASH_resolution x DASH x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: MASH resolution without worsening of fibrosis (biopsy)
- Diet: DASH (low-sodium, fruits, low-fat dairy)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 6. PNPLA3 rs738409 x efruxifermin x fibrosis_improvement x Korean_LF_HC x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: >=1 stage fibrosis improvement without worsening of MASH (biopsy)
- Diet: Korean low-fat high-carb (rice-based, ~65% carb)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 7. PNPLA3 rs738409 x efruxifermin x fibrosis_improvement x Mediterranean x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: >=1 stage fibrosis improvement without worsening of MASH (biopsy)
- Diet: Mediterranean (olive oil, fish, vegetables)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 8. PNPLA3 rs738409 x efruxifermin x fibrosis_improvement x low_carb x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: >=1 stage fibrosis improvement without worsening of MASH (biopsy)
- Diet: Low-carb (<26% kcal carb)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 9. PNPLA3 rs738409 x efruxifermin x fibrosis_improvement x ketogenic x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: >=1 stage fibrosis improvement without worsening of MASH (biopsy)
- Diet: Ketogenic (<10% kcal carb, high fat)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 10. PNPLA3 rs738409 x efruxifermin x fibrosis_improvement x DASH x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: >=1 stage fibrosis improvement without worsening of MASH (biopsy)
- Diet: DASH (low-sodium, fruits, low-fat dairy)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 11. PNPLA3 rs738409 x efruxifermin x PDFF_reduction_30 x Korean_LF_HC x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: >=30% relative reduction in MRI-PDFF (liver fat)
- Diet: Korean low-fat high-carb (rice-based, ~65% carb)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 12. PNPLA3 rs738409 x efruxifermin x PDFF_reduction_30 x Mediterranean x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: >=30% relative reduction in MRI-PDFF (liver fat)
- Diet: Mediterranean (olive oil, fish, vegetables)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 13. PNPLA3 rs738409 x efruxifermin x PDFF_reduction_30 x low_carb x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: >=30% relative reduction in MRI-PDFF (liver fat)
- Diet: Low-carb (<26% kcal carb)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 14. PNPLA3 rs738409 x efruxifermin x PDFF_reduction_30 x ketogenic x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: >=30% relative reduction in MRI-PDFF (liver fat)
- Diet: Ketogenic (<10% kcal carb, high fat)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 15. PNPLA3 rs738409 x efruxifermin x PDFF_reduction_30 x DASH x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: >=30% relative reduction in MRI-PDFF (liver fat)
- Diet: DASH (low-sodium, fruits, low-fat dairy)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 16. PNPLA3 rs738409 x efruxifermin x VCTE_reduction_20 x Korean_LF_HC x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: >=20% relative reduction in VCTE (FibroScan) liver stiffness
- Diet: Korean low-fat high-carb (rice-based, ~65% carb)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 17. PNPLA3 rs738409 x efruxifermin x VCTE_reduction_20 x Mediterranean x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: >=20% relative reduction in VCTE (FibroScan) liver stiffness
- Diet: Mediterranean (olive oil, fish, vegetables)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 18. PNPLA3 rs738409 x efruxifermin x VCTE_reduction_20 x low_carb x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: >=20% relative reduction in VCTE (FibroScan) liver stiffness
- Diet: Low-carb (<26% kcal carb)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 19. PNPLA3 rs738409 x efruxifermin x VCTE_reduction_20 x ketogenic x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: >=20% relative reduction in VCTE (FibroScan) liver stiffness
- Diet: Ketogenic (<10% kcal carb, high fat)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 20. PNPLA3 rs738409 x efruxifermin x VCTE_reduction_20 x DASH x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: >=20% relative reduction in VCTE (FibroScan) liver stiffness
- Diet: DASH (low-sodium, fruits, low-fat dairy)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 21. PNPLA3 rs738409 x efruxifermin x MRE_reduction_15 x Korean_LF_HC x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: >=15% relative reduction in MRE liver stiffness
- Diet: Korean low-fat high-carb (rice-based, ~65% carb)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 22. PNPLA3 rs738409 x efruxifermin x MRE_reduction_15 x Mediterranean x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: >=15% relative reduction in MRE liver stiffness
- Diet: Mediterranean (olive oil, fish, vegetables)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 23. PNPLA3 rs738409 x efruxifermin x MRE_reduction_15 x low_carb x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: >=15% relative reduction in MRE liver stiffness
- Diet: Low-carb (<26% kcal carb)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 24. PNPLA3 rs738409 x efruxifermin x MRE_reduction_15 x ketogenic x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: >=15% relative reduction in MRE liver stiffness
- Diet: Ketogenic (<10% kcal carb, high fat)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 25. PNPLA3 rs738409 x efruxifermin x MRE_reduction_15 x DASH x East_Asian
- score: **0.934**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: efruxifermin (FGF21 analog, Phase 3)
- Outcome: >=15% relative reduction in MRE liver stiffness
- Diet: DASH (low-sodium, fruits, low-fat dairy)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.80, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.80

## 26. PNPLA3 rs738409 x pegozafermin x MASH_resolution x Korean_LF_HC x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: MASH resolution without worsening of fibrosis (biopsy)
- Diet: Korean low-fat high-carb (rice-based, ~65% carb)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 27. PNPLA3 rs738409 x pegozafermin x MASH_resolution x Mediterranean x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: MASH resolution without worsening of fibrosis (biopsy)
- Diet: Mediterranean (olive oil, fish, vegetables)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 28. PNPLA3 rs738409 x pegozafermin x MASH_resolution x low_carb x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: MASH resolution without worsening of fibrosis (biopsy)
- Diet: Low-carb (<26% kcal carb)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 29. PNPLA3 rs738409 x pegozafermin x MASH_resolution x ketogenic x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: MASH resolution without worsening of fibrosis (biopsy)
- Diet: Ketogenic (<10% kcal carb, high fat)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 30. PNPLA3 rs738409 x pegozafermin x MASH_resolution x DASH x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: MASH resolution without worsening of fibrosis (biopsy)
- Diet: DASH (low-sodium, fruits, low-fat dairy)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 31. PNPLA3 rs738409 x pegozafermin x fibrosis_improvement x Korean_LF_HC x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: >=1 stage fibrosis improvement without worsening of MASH (biopsy)
- Diet: Korean low-fat high-carb (rice-based, ~65% carb)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 32. PNPLA3 rs738409 x pegozafermin x fibrosis_improvement x Mediterranean x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: >=1 stage fibrosis improvement without worsening of MASH (biopsy)
- Diet: Mediterranean (olive oil, fish, vegetables)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 33. PNPLA3 rs738409 x pegozafermin x fibrosis_improvement x low_carb x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: >=1 stage fibrosis improvement without worsening of MASH (biopsy)
- Diet: Low-carb (<26% kcal carb)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 34. PNPLA3 rs738409 x pegozafermin x fibrosis_improvement x ketogenic x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: >=1 stage fibrosis improvement without worsening of MASH (biopsy)
- Diet: Ketogenic (<10% kcal carb, high fat)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 35. PNPLA3 rs738409 x pegozafermin x fibrosis_improvement x DASH x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: >=1 stage fibrosis improvement without worsening of MASH (biopsy)
- Diet: DASH (low-sodium, fruits, low-fat dairy)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 36. PNPLA3 rs738409 x pegozafermin x PDFF_reduction_30 x Korean_LF_HC x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: >=30% relative reduction in MRI-PDFF (liver fat)
- Diet: Korean low-fat high-carb (rice-based, ~65% carb)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 37. PNPLA3 rs738409 x pegozafermin x PDFF_reduction_30 x Mediterranean x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: >=30% relative reduction in MRI-PDFF (liver fat)
- Diet: Mediterranean (olive oil, fish, vegetables)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 38. PNPLA3 rs738409 x pegozafermin x PDFF_reduction_30 x low_carb x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: >=30% relative reduction in MRI-PDFF (liver fat)
- Diet: Low-carb (<26% kcal carb)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 39. PNPLA3 rs738409 x pegozafermin x PDFF_reduction_30 x ketogenic x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: >=30% relative reduction in MRI-PDFF (liver fat)
- Diet: Ketogenic (<10% kcal carb, high fat)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 40. PNPLA3 rs738409 x pegozafermin x PDFF_reduction_30 x DASH x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: >=30% relative reduction in MRI-PDFF (liver fat)
- Diet: DASH (low-sodium, fruits, low-fat dairy)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 41. PNPLA3 rs738409 x pegozafermin x VCTE_reduction_20 x Korean_LF_HC x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: >=20% relative reduction in VCTE (FibroScan) liver stiffness
- Diet: Korean low-fat high-carb (rice-based, ~65% carb)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 42. PNPLA3 rs738409 x pegozafermin x VCTE_reduction_20 x Mediterranean x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: >=20% relative reduction in VCTE (FibroScan) liver stiffness
- Diet: Mediterranean (olive oil, fish, vegetables)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 43. PNPLA3 rs738409 x pegozafermin x VCTE_reduction_20 x low_carb x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: >=20% relative reduction in VCTE (FibroScan) liver stiffness
- Diet: Low-carb (<26% kcal carb)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 44. PNPLA3 rs738409 x pegozafermin x VCTE_reduction_20 x ketogenic x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: >=20% relative reduction in VCTE (FibroScan) liver stiffness
- Diet: Ketogenic (<10% kcal carb, high fat)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 45. PNPLA3 rs738409 x pegozafermin x VCTE_reduction_20 x DASH x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: >=20% relative reduction in VCTE (FibroScan) liver stiffness
- Diet: DASH (low-sodium, fruits, low-fat dairy)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 46. PNPLA3 rs738409 x pegozafermin x MRE_reduction_15 x Korean_LF_HC x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: >=15% relative reduction in MRE liver stiffness
- Diet: Korean low-fat high-carb (rice-based, ~65% carb)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 47. PNPLA3 rs738409 x pegozafermin x MRE_reduction_15 x Mediterranean x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: >=15% relative reduction in MRE liver stiffness
- Diet: Mediterranean (olive oil, fish, vegetables)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 48. PNPLA3 rs738409 x pegozafermin x MRE_reduction_15 x low_carb x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: >=15% relative reduction in MRE liver stiffness
- Diet: Low-carb (<26% kcal carb)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 49. PNPLA3 rs738409 x pegozafermin x MRE_reduction_15 x ketogenic x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: >=15% relative reduction in MRE liver stiffness
- Diet: Ketogenic (<10% kcal carb, high fat)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78

## 50. PNPLA3 rs738409 x pegozafermin x MRE_reduction_15 x DASH x East_Asian
- score: **0.930**
- SNP: PNPLA3 rs738409 (I148M missense; loss of TG hydrolase activity)
- Drug: pegozafermin (FGF21 analog, Phase 3)
- Outcome: >=15% relative reduction in MRE liver stiffness
- Diet: DASH (low-sodium, fruits, low-fat dairy)
- Ethnic: East_Asian (allele freq 0.420)
- Evidence: PubMed=0, GWAS_supporting=4, trial_stratified=False, mechanism_plaus=0.78, korean_lean_N~1800
- 선정 사유: PubMed 0건 (미보고 조합); GWAS 다수 phenotype 지원; East_Asian 빈도 0.42 (고빈도); 주요 RCT에서 미층화; 기전적 타당성 0.78